BPLPHARMA1,560.00

Bharat Parenterals Limited

· Pharma & Health
₹ CrorePeersJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
Returns
Return on Common Equity12.8212.74
Return on Assets9.777.90
Return on Invested Capital9.886.13
Margins
EBITDA Margin13.289.80
Operating Margin10.137.12
Incremental Operating Margin-100.03
Pretax Margin13.3814.76
Net Income Margin10.0511.16
FCF Margin-5.30
Additional
Effective Tax Rate25.9324.35
Sustainable Growth Rate12.8212.74
Incremental Operating Margin %-100.03
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY23 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.